Aldeyra Resubmits NDA for DED Drug Reproxalap episode artwork

EPISODE · Oct 9, 2024 · 4 MIN

Aldeyra Resubmits NDA for DED Drug Reproxalap

from Eyewire News: The Podcast · host Eyewire News

Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace. Learn more about your ad choices. Visit megaphone.fm/adchoices

Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace. Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Aldeyra Resubmits NDA for DED Drug Reproxalap

0:00 4:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 4 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on October 9, 2024.

What is this episode about?

Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace. Learn more about your ad...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!